Rehovot-based therapeutics company Pharmos has received a $1.3 million grant from the Office of the Chief Scientist for the development of the company's drug treatment for moderate-to-severe pain indications, the CB2-selective platform of synthetic cannabinoids.
About 50 percent of the funding is allocated for research and development expenditures within Israel and 50% is allocated for international expenditures for the fiscal 2006. A portion of the grant will be applied to late-stage preclinical and clinical costs for developing cannabinor, the company's lead CB2-selective drug candidate for the treatment of pain.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>